Nephrol Dial Transplant (2000) 15: 1367-1372
© 2000 European Renal Association-European Dialysis and Transplant Association
Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus
1 Medizinische Universitätsklinik, Abteilungen Innere Medizin III and 2 II, Tübingen, and 3 Malteser Krankenhaus, Flensburg, Germany
Background. Reduction of pathological autoantibodies and circulating immune complexes can be useful in the treatment of autoimmune disease. Plasmapheresis has been shown to reduce autoantibody levels in systemic lupus erythematosus (SLE), but its effect on patients' outcome was not better compared with conventional immunosuppression in the past.
Aim of the study. Immunoadsorption as a selective extracorporeal immunoglobulin elimination technique was evaluated as rescue therapy in patients suffering from SLE.
Methods. Eight patients with severe, therapy-resistant SLE underwent immunoadsorption onto protein A sepharose without concomitant immunosuppressants.
Results. Remission of the disease was achieved in seven patients. Therapy had to be stopped in one patient because of side-effects. The best results were obtained when immunoadsorption was carried out daily, without supplementary intravenous immunoglobulin therapy. Oral cyclophosphamide for 3–6 months during follow-up was used to suppress relapse. Autoantibodies and circulating immune complexes were effectively eliminated regardless of their IgG subclass.
Conclusion. Immunoadsorption onto protein A might be used as an extracorporeal treatment option in SLE when other therapies are ineffective.
Keywords: autoantibody; immune complexes; immunoadsorption; immunoglobulin subclasses; lupus nephritis; protein A
Correspondence and offprint requests to: Dr Norbert Braun MD, Medizinische Klinik and Poliklinik, Abteilung III, Sektion Nieren- and Hochdruckkrankheiten, Otfried-Müller-Str. 10, D-72076 Tübingen, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. A. Heyneman Systemic Lupus Erythematosus: A Therapeutic Update Journal of Pharmacy Practice, February 1, 2009; 22(1): 29 - 52. [Abstract] [PDF]
|
|
|
|
 |
|
 C Pagnoux, J-M Korach, and L Guillevin Indications for plasma exchange in systemic lupus erythematosus in 2005 Lupus, November 1, 2005; 14(11): 871 - 877. [Abstract] [PDF]
|
|
|
|
|
|
P Willeke, B Schluter, H Schotte, M Erren, E Mickholz, W Domschke, and M Gaubitz Increased frequency of GM-CSF secreting PBMC in patients with active systemic lupus erythematosus can be reduced by immunoadsorption Lupus, April 1, 2004; 13(4): 257 - 262. [Abstract] [PDF]
|
|
|
|
|
|
K Lhotta, R Wurzner, A R Rosenkranz, R Beer, A Rudisch, F Neumair, and G Mayer Cerebral vasculitis in a patient with hereditary complete C4 deficiency and systemic lupus erythematosus Lupus, February 1, 2004; 13(2): 139 - 141. [Abstract] [PDF]
|
|
|
|
 |
|
 C C Mok, R W S Wong, and K N Lai Treatment of severe proliferative lupus nephritis: the current state Ann Rheum Dis, September 1, 2003; 62(9): 799 - 804. [Abstract] [Full Text] [PDF]
|
|